Pharmacare News Bulletins

Pharmacy edition

Latest Issues

November Bulletin Vol 25-15 (PDF)
New Exception Status Products: Ferinject (ferric carboxymaltose), Noyada (captopril), Pexegra (pegfilgrastim); Criteria Updates: Dimethyl Fumarate, Teriflunomide, Wet Nebulization Solutions (Ipratropium Bromide, Salbutamol, Ipratropium Bromide and Salbutamol); Change in Benefit Status; New Benefits; Removal of PRP From Drug Products.

October Bulletin Vol 25-14 (PDF)
New Exception Status Products: Bylvay (odevixibat), Fruzaqla (fruquintinib), Rystiggo (rozanolixizumab), Tibsovo (ivosidenib), Zilbrysq (zilucoplan), Omlyclo (omalizumab); Criteria Updates: Venclexta (venetoclax), Steqeyma (ustenkinumab); Change in Benefit Status; Administration of Publicly Funded Influenza and COVID-19 Vaccinations Provided by a Pharmacy.

September Bulletin Vol 25-13 (PDF)
New Exception Status Products: Aflivu (aflibercept), Yesafili (aflibercept), Evkeeza (evinacumab), Leqvio (inclisiran); Criteria Update: Ultomiris (ravulizumab).

September Bulletin Vol 25 – 12 (PDF)
Pharmacists’ Administration of Respiratory Syncytial Virus (RSV) Vaccine for Nova Scotians 75 years and Older.

August Bulletin Vol 25-11 (PDF)
Criteria and Benefit Status Updates for Chronic Obstructive Pulmonary Disease (COPD) and Asthma Inhalers; New Exception Status Benefits: Apretude (cabotegravir), Imcivree (setmelanotide), Livmarli (maralixibat), Myalepta (metreleptin), Byooviz (ranibizumab), Eylea (aflibercept), Eylea HD (aflibercept), Ranopto (ranibizumab), Vabysmo (faricimab); Criteria Updates: Xtandi (enzalutamide), Emtricitabine and Tenofovir Disoproxil; Change in Benefit Status; New Benefits; Temporary Benefits.

July Bulletin Vol 25-10 (PDF)
New Exception Status Benefits: Uplizna (inebilizumab), Lysodren (mitotane); Criteria Update: Alecensaro (alectinib); New Benefits

June Bulletin Vol 25-09 (PDF)
New Exception Status Benefits: Vascepa (icosapent ethyl), Velsipity (etrasimod), Vyvgart (efgartigimod alfa), Wainua (eplontersen); Criteria Update: Cosentyx (Secukinumab); Change in Benefit Status; New Benefits; Uncomplicated Cystitis Service Expansion.

May Bulletin Vol 25-08 (PDF)
New Exception Status Benefits: Epidiolex (cannabidiol), Tyenne (tocilizumab), Xcopri (cenobamate), Cabtreo (adapalene/benzoyl peroxide/clindamycin); Coverage Updates: Aubagio and generics (teriflunomide), Gilenya and generics (fingolimod), Glatect, Copaxone and generic (glatiramer acetate), Interferon Beta-1A and 1B, Kesimpta (ofatumumab), Mayzent (spinonimod), Ocrevus (ocrelizumab), Tecfidera and generics (dimethyl fumarate), Tysabri (natalizumab); Change in Benefit Status, New Benefits, Pharmacists' Administration of Vaccines: for Prevention of Herpes Zoster and Pneumococcal Disease.

April Bulletin Vol 25-07 (PDF)
New Exception Status Product: Osnuvo (teriparatide); Criteria Updates: Bimzelx (bimekizumab), Imbruvica (ibrutinib), Tagrisso (osimertinib), Venclexta (venetoclax), Cipro (ciprofloxacin and generics), Levaquin (levofloxacin and generics), Avelox (moxifloxacin and generics), Norfloxacin; Change in Benefit Status; New Benefits

March Bulletin Vol 25-06 (PDF)
Infliximab IV IV (Inflectra) Changes and New Infliximab IV Products ,New Exception Status Products; Sohonos (palovarotene); Ticagrelor (Brilinta and generic brands); Truqap (capivasertib) Change in Benefit Status
New Benefits

March Bulletin Vol 25-05 (PDF)
Infliximab IV (Inflectra) Changes Changes for Submission of Claims over $9,999.99.

March Bulletin Vol 25-04 (PDF)
Pharmacists' Administration of Respiratory Syncytial Virus (RSV) Vaccine in Long-term Care Facilities and Residential Care Facilities

February Bulletin Vol 25-03 (PDF)
New Exception Status Benefits: Koselugo (selumetinib), Remsima SC (infliximab), Welireg (belzutifan); Criteria Update: Kerendia (finerenone); Coverage Period Updates for Biologics and Janus Kinase (JAK) Inhibitors.

February Bulletin Vol 25-02 (PDF)
Nova Scotia Formulary Updates, Physician Assistant and Podiatrist Prescribing

January Bulletin Vol 25-01 (PDF)
New Exception Status Products: Amvuttra (vutrisiran), Orladeyo (berotralstat hydrochloride) Criteria Update, Verzenio (abemaciclib) New Benefits Generic Drug Pricing Reminder Auditor’s Corner